|
Dec 22
|
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
|
|
Dec 22
|
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
|
|
Dec 22
|
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics in $14 Billion Pharma Deal
|
|
Dec 22
|
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
|
|
Dec 22
|
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
|
|
Dec 22
|
Bristol Myers acquiring Karuna Therapeutics in $14B deal
|
|
Dec 22
|
3 Attractive Healthcare Dividend Stocks for 2024
|
|
Dec 22
|
5 Things to Know Before The Stock Market Opens
|
|
Dec 22
|
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
|
|
Dec 22
|
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
|
|
Dec 22
|
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
|
|
Dec 22
|
Bristol Myers to acquire brain drug developer Karuna for $14B
|
|
Dec 21
|
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
|
|
Dec 10
|
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
|
|
Dec 10
|
12 Healthcare Stocks Billionaires Like the Most
|
|
Dec 10
|
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.60
|
|
Dec 9
|
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
|
|
Dec 8
|
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
|